BDC-3042

N/A

Report date: 2025/11/18 20:00:06
First In Class

Base Information

Drug NameBDC-3042
Drug Alias NameBDC-3042
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionC-type lectin domain family 6 member A agonists
TargetsC-type lectin domain family 6 member A
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBolt Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBolt Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsOvarian Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A